IL6 and coronary artery disorder: In a large meta-analysis investigating the effects of colchicine on inflammatory markers in patients with CAD across 11 clinical trials, colchicine led to a significant reduction in hs-CRP (weighted mean differences (WMDs), −0.81 mg/L; 95% confidence interval (CI), −1.34 to 0.28 mg/L; P=0.003) and IL-6 levels (WMD, −1.28 pg/mL; 95% CI, −2.35 to −0.21 pg/mL; P=0.02) compared with placebo [29].